Bafna Pharmaceuticals Limited

NSEI:BAFNAPH Stock Report

Market Cap: ₹1.9b

Bafna Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bansilal Mahaveer Bafna

Chief executive officer

₹7.5m

Total compensation

CEO salary percentagen/a
CEO tenure19yrs
CEO ownership0.2%
Management average tenure7.6yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Investors Don't See Light At End Of Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Tunnel

Jul 03
Investors Don't See Light At End Of Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Tunnel

We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt

Aug 15
We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt

Optimistic Investors Push Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Shares Up 27% But Growth Is Lacking

Feb 13
Optimistic Investors Push Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Shares Up 27% But Growth Is Lacking

The Strong Earnings Posted By Bafna Pharmaceuticals (NSE:BAFNAPH) Are A Good Indication Of The Strength Of The Business

Nov 19
The Strong Earnings Posted By Bafna Pharmaceuticals (NSE:BAFNAPH) Are A Good Indication Of The Strength Of The Business

Do Its Financials Have Any Role To Play In Driving Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Stock Up Recently?

Dec 10
Do Its Financials Have Any Role To Play In Driving Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Stock Up Recently?

CEO Compensation Analysis

How has Bansilal Mahaveer Bafna's remuneration changed compared to Bafna Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹4m

Jun 30 2024n/an/a

₹3m

Mar 31 2024₹8mn/a

₹73m

Dec 31 2023n/an/a

₹113m

Sep 30 2023n/an/a

₹172m

Jun 30 2023n/an/a

₹163m

Mar 31 2023₹4mn/a

₹113m

Dec 31 2022n/an/a

₹50m

Sep 30 2022n/an/a

₹37m

Jun 30 2022n/an/a

₹44m

Mar 31 2022₹4mn/a

₹52m

Dec 31 2021n/an/a

₹88m

Sep 30 2021n/an/a

₹80m

Jun 30 2021n/an/a

₹61m

Mar 31 2021₹3mn/a

₹58m

Dec 31 2020n/an/a

₹256m

Sep 30 2020n/an/a

₹28m

Jun 30 2020n/an/a

₹18m

Mar 31 2020₹2m₹2m

-₹19m

Dec 31 2019n/an/a

-₹394m

Sep 30 2019n/an/a

-₹178m

Jun 30 2019n/an/a

-₹196m

Mar 31 2019₹2m₹2m

-₹199m

Mar 31 2018₹2m₹2m

-₹167m

Compensation vs Market: Bansilal Mahaveer's total compensation ($USD88.04K) is above average for companies of similar size in the Indian market ($USD42.28K).

Compensation vs Earnings: Bansilal Mahaveer's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Bansilal Mahaveer Bafna (63 yo)

19yrs

Tenure

₹7,518,000

Compensation

Mr. Bansilal Mahaveer Chand Bafna has been Chief Executive Officer of Bafna Pharmaceuticals Limited since September 10, 2020 and served as Chairman and Managing Director of Bafna Pharmaceuticals Limited si...

Leadership Team

NamePositionTenureCompensationOwnership
Bansilal Mahaveer Bafna
Chief Executive Officer19yrs₹7.52m0.20%
₹ 3.9m
Melagiri Sridhar
Chief Financial Officer7.6yrs₹1.37mno data
Vinayak Dendukuri
Whole-Time Director of Qualityno data₹2.21mno data
Shanmugam Hemalatha
Executive Chairman4.3yrsno datano data
A. Mohanachandran
Company Secretary & Compliance Officerless than a yearno datano data

7.6yrs

Average Tenure

52.5yo

Average Age

Experienced Management: BAFNAPH's management team is seasoned and experienced (7.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vinayak Dendukuri
Whole-Time Director of Quality1.5yrs₹2.21mno data
Shanmugam Hemalatha
Executive Chairman4.3yrsno datano data
Palamadai Sundaresan
Non-Executive & Independent Director4.5yrs₹121.00kno data
Upendar Reddy
Additional Non-Executive Non-Independent Director1.5yrs₹55.00kno data
Ravichandran Chitra
Non-Executive & Independent Director4.1yrs₹110.00kno data
Akilapriya Chintalapati Raju
Non-Executive & Non-Independent Director4.3yrs₹88.00kno data
Krishna Yeachuri
Non-Executive Independent Director1.5yrs₹22.00kno data

4.1yrs

Average Tenure

46yo

Average Age

Experienced Board: BAFNAPH's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 02:59
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bafna Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution